Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Assets: 2020-2025

Historic Non-Current Assets for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $20.8 million.

  • Foghorn Therapeutics' Non-Current Assets fell 43.87% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 43.87%. This contributed to the annual value of $34.4 million for FY2024, which is 24.83% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Non-Current Assets of $20.8 million as of Q3 2025, which was down 6.92% from $22.4 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Non-Current Assets ranged from a high of $64.6 million in Q1 2021 and a low of $20.8 million during Q3 2025.
  • In the last 3 years, Foghorn Therapeutics' Non-Current Assets had a median value of $39.0 million in 2024 and averaged $38.7 million.
  • Data for Foghorn Therapeutics' Non-Current Assets shows a maximum YoY plummeted of 43.87% (in 2025) over the last 5 years.
  • Over the past 5 years, Foghorn Therapeutics' Non-Current Assets (Quarterly) stood at $60.2 million in 2021, then fell by 11.17% to $53.5 million in 2022, then dropped by 14.49% to $45.7 million in 2023, then fell by 24.83% to $34.4 million in 2024, then plummeted by 43.87% to $20.8 million in 2025.
  • Its last three reported values are $20.8 million in Q3 2025, $22.4 million for Q2 2025, and $33.3 million during Q1 2025.